Clinical trial
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
NCT05733546 is registered in ClinicalTrials.gov with COMPASS Pathways as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
- Lead sponsor
- COMPASS Pathways
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 30, 2023
- Completion date
- September 30, 2025
- Enrollment
- 102 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.